IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma

Melief, S.M.; Visser, M.; Burg, S.H. van der; Verdegaal, E.M.E. (2017)

Article / Letter to editor

• Metastatic melanoma
• Adoptive cell transfer
• Immunotherapy
• GMP
• IDO
• Galectin-3

• All authors: Melief, S.M.; Visser, M.; Burg, S.H. van der; Verdegaal, E.M.E.
• Date: 2017-07-31
• Journal: Cancer Immunology, Immunotherapy
• Volume: 66
• Issue: 7
• Pages: 913 - 926
• DOI: doi:10.1007/s00262-017-1995-x